Do You Keep Losing Weight with Ozempic? Understanding the Journey

Last reviewed: June 8, 2026

Last updated: June 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Weight loss on semaglutide does not continue indefinitely — it decelerates and reaches a plateau, and the pivotal trials show where. In Wegovy Study 2, a 68-week trial of 1,961 patients with obesity or with overweight plus a weight-related comorbid condition, mean body weight fell 14.9% with semaglutide injection versus 2.4% with placebo, and the curve flattened well before the trial ended. It is also worth naming the product confusion up front: Ozempic is approved only for type 2 diabetes indications, while Wegovy carries the weight-management indications and generated the weight-loss trial data people are asking about.

The Shape of the Curve, Not Just the Endpoint

Weight trajectories on this class share a characteristic shape. Loss is fastest during the early months, slows through the middle of the first year, and approaches a plateau somewhere between roughly month nine and month sixteen depending on the trial and the agent. The 68-week and 72-week trial durations were chosen partly because that is how long the curve takes to settle.

Part of the early steepness is pharmacological. Semaglutide reaches steady-state exposure after four to five weeks of once-weekly administration, and dose escalation continues past that point, so exposure is still rising while weight is already falling.

The plateau is not a sign the medication stopped working. Maintaining a reduced weight against the body’s counter-regulatory response is itself an active effect, which is why the Wegovy indication is written as reducing excess body weight and maintaining weight reduction long term.

What the Trials Recorded Over Time

Wegovy Study 2 ran 68 weeks in patients without type 2 diabetes and reported a mean change of −14.9% versus −2.4% with placebo, a difference of −12.4 percentage points. Study 4, which paired the medication with intensive lifestyle therapy over the same duration, reported −16% versus −5.7%.

Study 3, in 807 patients with type 2 diabetes and body mass index of at least 27 kg/m², reported −9.6% versus −3.4%. The smaller magnitude in the diabetes population is a consistent and reproducible finding across this class, not a quirk of one trial.

Study 5 tested what happens with continued treatment after an initial 20-week run-in: of 902 patients, 803 reached the 2.4 mg maintenance dosage and were randomised to continue or to switch to placebo. That design exists precisely because the question of whether loss continues is the central one.

Why Individual Results Diverge From the Average

Every published percentage is a group mean. Within any trial arm there is wide dispersion — some participants far exceed the mean and some lose little. The trial reports proportions achieving 5%, 10% and 15% thresholds precisely because a single average conceals that spread.

Adherence explains a large share of real-world divergence. Real-world data cited in recent reviews indicate that a substantial proportion of GLP-1 receptor agonist users discontinue within a year of initiation, and intermittent use produces intermittent effect.

Concurrent conditions and concurrent medications matter as well, as does the degree to which the diet and activity component of the labeled regimen is actually in place. Every pivotal trial delivered structured lifestyle support alongside the drug.

The Plateau Is a Decision Point, Not a Failure

When the curve flattens, the clinical question shifts from "how much more" to "what are we maintaining and at what cost". The Wegovy label directs that treatment response and tolerability be considered when selecting a maintenance dosage, and it now permits an increase to a maximum of 7.2 mg once weekly for adults who have tolerated 2.4 mg for at least four weeks and for whom additional weight reduction is clinically indicated.

That maximum came from Study 8, a 72-week trial in 1,407 patients with obesity randomised 5:1:1 to 7.2 mg, 2.4 mg or placebo. Whether a higher maintenance dosage is appropriate for any individual is a prescriber’s judgement made against tolerability and response, not a default next step.

What Happens If You Stop

This is the part of the trajectory people plan for least. Randomised withdrawal trials across this class consistently show substantial weight regain after discontinuation, together with reversal of some cardiometabolic improvements. A 2026 review in EClinicalMedicine summarises that roughly two-thirds of lost weight is typically regained within a year of stopping.

Reviewers increasingly frame this as recurrence of a chronic relapsing condition once pharmacological appetite suppression is removed, rather than as failure of the treatment or of the person. Homeostatic weight-defence mechanisms re-emerge and push toward the previous set point.

Questions Worth Bringing to a Review Appointment

Ask what your own curve has actually done over the last three months rather than relying on week-to-week readings, which are dominated by fluid and glycogen shifts. Ask what the plan is for maintenance once the curve flattens, and what the plan is if you need to stop.

Ask about the things that are measurable besides weight: blood pressure, lipids, glycemia, waist circumference, and how you feel functionally. In SURMOUNT-5 waist circumference fell −18.4 cm with tirzepatide and −13.0 cm with semaglutide over 72 weeks, which is a reminder that scale weight is one output among several.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Does weight loss on semaglutide eventually stop?

It decelerates and plateaus rather than continuing indefinitely. In Wegovy Study 2, a 68-week trial, mean body weight change was minus 14.9% versus minus 2.4% with placebo, with the steepest decline in the early months. The plateau reflects the body defending a new weight rather than the medication ceasing to act, which is why the indication includes maintaining weight reduction long term.

How long does it take to reach a plateau?

The pivotal trials ran 68 to 72 weeks, and the weight curves in those trials flatten within that window rather than at a single fixed week. Individual trajectories vary widely around the group mean, which is why trial reports also give the proportions of participants reaching 5%, 10% and 15% loss rather than the average alone. Your prescriber tracks your own trend.

Why is my weight loss smaller than the trial numbers?

Published figures are group averages generated alongside structured diet and activity support, with participants receiving instruction for an approximately 500 kcal per day deficit and at least 150 minutes of activity per week. Individual results disperse widely around that mean, and adherence, concurrent medications and coexisting conditions such as type 2 diabetes all shift the expected magnitude.

Does a higher dose restart weight loss?

The Wegovy label now permits an increase to a maximum of 7.2 mg once weekly in adults who have tolerated 2.4 mg for at least four weeks and for whom additional weight reduction is clinically indicated, based on a 72-week trial in 1,407 patients. Whether that applies to you is a prescriber decision weighing response against tolerability, not an automatic next step.

Will I regain weight if I stop the medication?

Randomised withdrawal trials in this class consistently show substantial regain after discontinuation, and a 2026 review reports that roughly two-thirds of lost weight is typically regained within a year of stopping, alongside reversal of some cardiometabolic gains. Current reviews describe this as recurrence of a chronic relapsing condition rather than treatment failure. Plan any stop with your prescriber.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.